Christopher Davis

With the heaviest outflows last year, large growth, large value, and mid value could be tomorrow's winners.

Buying what others have been selling is a winning strategy.

Silver-rated Fidelity Select Health Care skillfully blends steady growers, fast-growing established firms with focused product lines, and emerging companies with innovative products.

The odds may be better for small-cap managers, but they're still long.

The tech rally and value slump have been headwinds for these Morningstar Medalists, but don't count them out.

The popularity of strategic-beta strategies risks dooming these funds to underperformance.

The decrease in the tech giant's shares are no cause for concern, says Fidelity manager Sonu Kalra, who suggests looking at past correlations between Apple's price movement and product cycles.

A look at the hits and misses in Fidelity's lineup.

Vanguard Health Care manager to step down.

An evolving strategy and high volatility dent this option's appeal.

Amid fears of long-term global systemic risk, investors are seeking to park cash in conservative vehicles that offer wealth preservation, income generation, and limited NAV volatility, says Fidelity's Bob Brown.

Fidelity manager Bob Brown says the European financial crisis will take years to resolve and that a continuing flight to quality will allow U.S. government bonds to sustain their value.

Ariel's John Rogers discusses recent opportunity in Madison Square Garden and International Speedway, as well as the firm's analytical adjustments in the wake of the financial crisis.

Fidelity is known for growth investing, but two up-and-coming managers invoke value investing legend Warren Buffett.

Better known for a sprawling suite of growth funds, Fidelity finally adds muscle to its value lineup.

FPA's Eric Bokota discusses his recipe for finding value in Europe for his new fund as well as why he's cautious of putting money into Asian names.

Magellan's large asset base gives the fund the ability to find growth stocks across the market-cap spectrum, says new manager Jeff Feingold.

You may have to moderate your expectations for dividend payers, but these offerings remain sound long-term options.

Fund managers say dividend-paying stocks became a "crowded trade" in 2011, but they still have long-term appeal.

The firm that gave birth to the celebrity manager takes a new tack.

RiverPark's founders apply the lessons they learned at Baron Capital to their own slate of funds.

After a spate of terrible performance, Fidelity finally hangs up on Harry Lange.

Fidelity's William Kennedy believes that fears of a debt downgrade are behind European leaders' timid response to the sovereign crisis.

Fidelity Low-Priced Stock's Tillinghast plans fourth-quarter leave.

It's not for lack of effort that the Boston behemoth's culture is just average.

Focus Consulting Group's Jim Ware discusses the corporate culture that lets some fund firms thrive while others lose ground.

Fidelity's supporting cast can deliver--sometimes.

Separating the most active managers from the index-huggers.

Funds in yesterday's unloved categories may be tomorrow's winners.

How to speculate without losing your shirt.

No, the 401(k) doesn't doom you to a substandard retirement.

Focusing too closely on income could leave you poorer in the end.

What investors should learn from 10 years of weak returns.

Fidelity's problem may not be the size of its small-cap funds but the girth of its larger siblings.

Despite thoughtfully conceived glide paths, the Freedom portfolios themselves are mostly a lesson in what investors shouldn't do on their own.

Manager of the Decade nominee Steve Romick of FPA Crescent on the fund's debt investments amid the crisis and finding opportunity in energy and health-care names today.

Even when it's tough to do your homework, you can be a well-informed investor.

A growing field of study can save you from your worst instincts.

No, the 401(k) doesn't doom you to a substandard retirement.

How to speculate without losing your shirt.

A growing field of study can save you from your worst instincts.

The fund company gets your checks, but it's someone else who calls the shots.

Fidelity scion Ned Johnson's offbeat portfolio is missing many of his firm's biggest funds.

The fund company gets your checks, but it's someone else who calls the shots.

A helping of risk has pushed the firm past the competition.

Focusing too closely on income could leave you poorer in the end.

An inside look at what motivates the Boston behemoth.

In this age of diminished expectations, how should you invest?

FPA's Bob Rodriguez and Tom Atteberry say the worst may be over, but the long recovery is just under way.

FPA's Bob Rodriguez discusses his decision to take a sabbatical from active management and transition planning at FPA.